Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to
evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in
patients with Major Depressive Disorder (MDD).